The impact of FcγRIIb during the effector phase of infectious disease vaccination, including those for influenza viruses, remains unclear, although the FcγRIIb-mediated suppression is deleterious for direct-targeting antibody therapeutics against cancer (Roghanian et al., 2018). The gene discussed is FCGR2B; the disease is infectious disease.